Compare Stocks: AQST, SUPN, PBH, and TRVI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$5.35 -0.6%	$4.26	$2.93 ▼ $7.55	$671.48M	1.48	3.09 million shs	1.83 million shs
PBH Prestige Consumer Healthcare	$52.63 -0.4%	$50.59	$42.62 ▼ $71.07	$2.49B	0.33	555,834 shs	449,101 shs
SUPN Supernus Pharmaceuticals	$43.97 -0.1%	$46.77	$42.45 ▼ $59.68	$2.56B	0.56	753,572 shs	390,319 shs
TRVI Trevi Therapeutics	$17.06 +0.1%	$18.00	$6.93 ▼ $20.22	$2.43B	1.04	1.71 million shs	1.43 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	+2.67%	-0.19%	+41.95%	+29.95%	+40.47%
PBH Prestige Consumer Healthcare	+0.10%	+1.53%	+1.97%	+16.38%	-20.44%
SUPN Supernus Pharmaceuticals	+0.66%	-1.89%	-4.28%	-1.50%	-1.15%
TRVI Trevi Therapeutics	+2.90%	-4.85%	-4.75%	+22.40%	+134.53%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$5.35 -0.6%	$4.26	$2.93 ▼ $7.55	$671.48M	1.48	3.09 million shs	1.83 million shs
PBH Prestige Consumer Healthcare	$52.63 -0.4%	$50.59	$42.62 ▼ $71.07	$2.49B	0.33	555,834 shs	449,101 shs
SUPN Supernus Pharmaceuticals	$43.97 -0.1%	$46.77	$42.45 ▼ $59.68	$2.56B	0.56	753,572 shs	390,319 shs
TRVI Trevi Therapeutics	$17.06 +0.1%	$18.00	$6.93 ▼ $20.22	$2.43B	1.04	1.71 million shs	1.43 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	+2.67%	-0.19%	+41.95%	+29.95%	+40.47%
PBH Prestige Consumer Healthcare	+0.10%	+1.53%	+1.97%	+16.38%	-20.44%
SUPN Supernus Pharmaceuticals	+0.66%	-1.89%	-4.28%	-1.50%	-1.15%
TRVI Trevi Therapeutics	+2.90%	-4.85%	-4.75%	+22.40%	+134.53%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	2.86	Moderate Buy	$8.80	64.49% Upside
PBH Prestige Consumer Healthcare	2.17	Hold	$70.75	34.43% Upside
SUPN Supernus Pharmaceuticals	2.71	Moderate Buy	$62.83	42.90% Upside
TRVI Trevi Therapeutics	3.00	Buy	$27.08	58.75% Upside

Current Analyst Ratings Breakdown

Latest AQST, SUPN, PBH, and TRVI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
8/14/2026	TRVI Trevi Therapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$24.00 ➝ $28.00
8/10/2026	PBH Prestige Consumer Healthcare	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/7/2026	TRVI Trevi Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$23.00
8/7/2026	TRVI Trevi Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$24.00 ➝ $25.00
8/7/2026	TRVI Trevi Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$40.00
8/7/2026	TRVI Trevi Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$25.00 ➝ $30.00
8/6/2026	SUPN Supernus Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/20/2026	TRVI Trevi Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$36.00
7/20/2026	TRVI Trevi Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/20/2026	TRVI Trevi Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$21.00 ➝ $31.00

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$44.54M	15.08	N/A	N/A	($0.45) per share	-11.89
PBH Prestige Consumer Healthcare	$1.10B	2.26	$5.21 per share	10.11	$40.46 per share	1.30
SUPN Supernus Pharmaceuticals	$718.95M	3.56	$3.79 per share	11.59	$17.74 per share	2.48
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$2.26 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$83.78M	-$0.65	N/A	N/A	N/A	-144.63%	N/A	-52.40%	11/4/2026 (Estimated)
PBH Prestige Consumer Healthcare	$190.30M	$3.57	14.74	10.34	1.65	15.57%	11.39%	5.66%	11/5/2026 (Estimated)
SUPN Supernus Pharmaceuticals	-$38.55M	-$1.92	N/A	11.39	0.81	-13.23%	11.13%	8.10%	11/3/2026 (Estimated)
TRVI Trevi Therapeutics	-$42.76M	-$0.34	N/A	N/A	N/A	N/A	-23.59%	-22.64%	11/12/2026 (Estimated)

Latest AQST, SUPN, PBH, and TRVI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	AQST Aquestive Therapeutics	-$0.1050	-$0.18	-$0.0750	-$0.18	$11.42 million	$13.82 million
8/6/2026	Q1 2027	PBH Prestige Consumer Healthcare	$0.8940	$0.98	+$0.0860	$0.61	$253.02 million	$265.71 million
8/6/2026	Q2 2026	TRVI Trevi Therapeutics	-$0.1095	-$0.11	-$0.0005	-$0.11	N/A	N/A
8/3/2026	Q2 2026 & Merger	SUPN Supernus Pharmaceuticals	$0.4225	-$1.01	-$1.4325	-$1.01	$205.31 million	$219.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
PBH Prestige Consumer Healthcare	$1.90	3.61%	N/A	53.22%	N/A
SUPN Supernus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	7.19	6.74
PBH Prestige Consumer Healthcare	1.06	3.23	1.99
SUPN Supernus Pharmaceuticals	N/A	2.08	1.84
TRVI Trevi Therapeutics	N/A	37.28	37.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
PBH Prestige Consumer Healthcare	99.95%
SUPN Supernus Pharmaceuticals	N/A
TRVI Trevi Therapeutics	95.76%

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	6.81%
PBH Prestige Consumer Healthcare	1.50%
SUPN Supernus Pharmaceuticals	8.50%
TRVI Trevi Therapeutics	15.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	160	125.51 million	116.97 million	Optionable
PBH Prestige Consumer Healthcare	540	47.38 million	46.66 million	Optionable
SUPN Supernus Pharmaceuticals	580	58.13 million	53.19 million	Optionable
TRVI Trevi Therapeutics	20	142.48 million	120.55 million	Optionable

AQST, SUPN, PBH, and TRVI Headlines

Recent News About These Companies

Trevi Therapeutics to Present at Multiple Healthcare and IPF Conferences in September 2026

September 3 at 7:51 AM | quiverquant.comQ

Trevi Therapeutics to Participate in Upcoming September Conferences

September 3 at 7:30 AM | globenewswire.com

Wellington Management Group LLP Boosts Stake in Trevi Therapeutics, Inc. $TRVI

September 2 at 4:56 AM | marketbeat.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $27.08 Average Price Target from Brokerages

August 30, 2026 | americanbankingnews.com

Jupiter Topco LLC Purchases New Position in Trevi Therapeutics, Inc. $TRVI

August 29, 2026 | marketbeat.com

Deutsche Bank AG Makes New Investment in Trevi Therapeutics, Inc. $TRVI

August 28, 2026 | marketbeat.com

BlackRock Inc. Acquires New Position in Trevi Therapeutics, Inc. $TRVI

August 28, 2026 | marketbeat.com

Artia Global Partners LP Purchases New Shares in Trevi Therapeutics, Inc. $TRVI

August 27, 2026 | marketbeat.com

Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026

August 26, 2026 | globenewswire.com

J. Goldman & Co LP Invests $1.51 Million in Trevi Therapeutics, Inc. $TRVI

August 26, 2026 | marketbeat.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Analysts

August 25, 2026 | marketbeat.com

Trevi Therapeutics Target of Unusually Large Options Trading (NASDAQ:TRVI)

August 23, 2026 | americanbankingnews.com

Bank of America Corp DE Has $14.52 Million Position in Trevi Therapeutics, Inc. $TRVI

August 22, 2026 | marketbeat.com

Stock Traders Purchase High Volume of Trevi Therapeutics Call Options (NASDAQ:TRVI)

August 21, 2026 | marketbeat.com

Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform

August 20, 2026 | seekingalpha.com

Flputnam Investment Management Co. Makes New $19.36 Million Investment in Trevi Therapeutics, Inc. $TRVI

August 17, 2026 | marketbeat.com

Walleye Capital LLC Purchases Shares of 241,987 Trevi Therapeutics, Inc. $TRVI

August 15, 2026 | marketbeat.com

JonesTrading Forecasts Strong Price Appreciation for Trevi Therapeutics (NASDAQ:TRVI) Stock

August 14, 2026 | marketbeat.com

HC Wainwright Issues Pessimistic Estimate for TRVI Earnings

August 13, 2026 | marketbeat.com

Sei Investments Co. Has $933,000 Holdings in Trevi Therapeutics, Inc. $TRVI

August 13, 2026 | marketbeat.com

What is HC Wainwright's Forecast for TRVI FY2030 Earnings?

August 12, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST, SUPN, PBH, and TRVI Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$5.35 -0.03 (-0.56%)

As of 04:00 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Prestige Consumer Healthcare NYSE:PBH

$52.63 -0.20 (-0.38%)

As of 03:58 PM Eastern

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Supernus Pharmaceuticals NASDAQ:SUPN

$43.97 -0.06 (-0.14%)

As of 04:00 PM Eastern

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Trevi Therapeutics NASDAQ:TRVI

$17.06 +0.01 (+0.06%)

As of 04:00 PM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AQST, SUPN, PBH, and TRVI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AQST, SUPN, PBH, and TRVI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AQST, SUPN, PBH, and TRVI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST, SUPN, PBH, and TRVI Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

Prestige Consumer Healthcare NYSE:PBH

Supernus Pharmaceuticals NASDAQ:SUPN

Trevi Therapeutics NASDAQ:TRVI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AQST, SUPN, PBH, and TRVI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AQST, SUPN, PBH, and TRVI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AQST, SUPN, PBH, and TRVI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST, SUPN, PBH, and TRVI Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

Prestige Consumer Healthcare NYSE:PBH

Supernus Pharmaceuticals NASDAQ:SUPN

Trevi Therapeutics NASDAQ:TRVI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools